Dogwood Therapeutics Inc(DWTX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -8.95 | Insider Own | 74.09% | Shs Outstand | 33.6M | Perf Week | -11.54% |
| Market Cap | 0.04B | Forward P/E | - | EPS next Y | 17.71% | Insider Trans | - | Shs Float | 8.8M | Perf Month | -28.12% |
| Enterprise Value | 0.03B | PEG | - | EPS next Q | -0.15 | Inst Own | 11.26% | Short Float | 0.44% | Perf Quarter | -21.23% |
| Income | -0.04B | P/S | - | EPS this Y | 87.73% | Inst Trans | 1.08% | Short Ratio | 0.56 | Perf Half Y | -24.59% |
| Sales | 0.00B | P/B | 0.57 | EPS next 5Y | 52.48% | ROA | -40.68% | Short Interest | 0.04M | Perf YTD | -72.36% |
| Book/sh | 2.03 | P/C | 4.07 | EPS past 3/5Y | 36.34% 25.53% | ROE | -47.77% | 52W High | -83.67% ($7.04) | Perf Year | -81.42% |
| Cash/sh | 0.28 | P/FCF | - | Sales past 3/5Y | - | ROIC | -52.66% | 52W Low | -2.54% ($1.18) | Perf 3Y | -92.65% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 52.36% | Gross Margin | - | Volatility(W/M) | 11.04% 10.07% | Perf 5Y | -99.04% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.14 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 3.89 | EPS Q/Q | 83.04% | Profit Margin | - | RSI (14) | 23.85 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.89 | Sales Q/Q | - | SMA20 | -15.75% ($1.36) | Beta | 2.08 | Target Price | $13.5 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/13 | SMA50 | -37.04% ($1.83) | Rel Volume | 0.73 | Prev Close | $1.21 |
| Employees | 8 | LT Debt/Eq | 0 | EPS/Sales Surpr. | -142.86% - | SMA200 | -44.2% ($2.06) | Avg Volume(3M) | 0.07M | Price | $1.15 |
| IPO | 2020/12/17 | Option/Short | No/Yes | Trades | 368 | Volume | 50,352 | Change | -4.96% |
🧪 This is a clinical-stage biopharmaceutical company developing innovative antiviral and neuropathic treatments for non-opioid pain therapies and intractable conditions such as chronic fatigue syndrome.
Over the past 1 year, on the lower side
84% below its 1-year high.
Traded less than usual. That is 73% of its average volume.
DWTX has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +87.7% this year.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.0%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 11.3%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
IWC iShares Micro-Cap ETF <0.01% 
VXF Vanguard Extended Market Index ETF <0.01% It ranks #439 of 595 in the industry
Based on market cap of $39M.
TIL#438 Instil Bio Inc $40M PER - DWTX#439 Dogwood Therapeutics Inc $39M PER - 
EXOZ#440 eXoZymes Inc $38M PER - 
EDSA#441 Edesa Biotech Inc $38M PER - 
NNVC#442 NanoViricides Inc $38M PER - 
FAQ
What kind of company is DWTX?
DWTX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of DWTX?
The market cap of DWTX is approximately $39M, ranking 4,984 within its sector.
What is the 52-week high and low for DWTX?
DWTX has recorded a 52-week high of $7.04 and a low of $1.18.
